Women’s libido drug take two: bremelanotide
Bremelanotide, an experimental treatment for low or absent sexual desire in women, moved closer to the clinic Tuesday, following positive Phase 3 trial results.
Morning Read: Valeant slashes sales staff for women’s libido pill Addyi
Also, Gilead made a deal worth up to $1.2 billion to acquire drugs that treat NASH and liver cancer.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
Even on CBS, Colbert takes aim at pharma, namely Addyi
Stephen Colbert, new host of "The Late Show with Stephen Colbert" on CBS — not the fake conservative pundit he played on "The Report" — can derive plenty of humor from needling the pharma industry.
From Denver’s new digital health center to a doctor’s take on Addyi approval: 5 must-read stories from MedCity News this week
A developer and a healthcare entrepreneur are planning a 300,000-square-foot digital health center in Denver, in a big to make the city the “digital health capital” of the U.S., and a doctor voices excitement over Addyi's approval.
Some doctors are speaking out about concerns with the FDA’s approval of Addyi
The approval of Addyi, or "female Viagra," has received a lot of hype, but is it worth it from a doctor's perspective?
Top sex doc on FDA approval of Addyi, women’s libido pill: ‘A nuclear bomb has exploded in women’s sexual health’
Dr. Irwin Goldstein, president of the Institute for Sexual Medicine, extolled the approval of Addyi, the first-ever drug approved to treat women's sexual dysfunction. He says it'll open the door for further conversation and research about women's health.
presented by
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.